Ultrasonic vs. Fluoroscopic Guided PNL in Pediatric Renal Stones

Status Recruiting

Clinical Trial Summary

Percutaneous Nephrolithotomy (PNL) was accepted as a treatment modality for large renal stones since 1980. Although radiation exposure during PNL is within the safe limits for expert endourologist, the mutagenic hazard is still present especially in pediatric population. Therefore, employing an alternative imaging technique during PNL would be of added advantage. So, the investigators want to compare the efficacy of ultrasound guided PNL with the conventional (fluoroscopy guided) PNL in pediatric population. If ultrasound guided PNL was as effective as conventional one, this means that many children could be protected from the variable hazards of radiation exposure.

Clinical Trial Description

The incidence of pediatric urolithiasis varies by geographic area. Most cases of pediatric urolithiasis are associated with anatomic or metabolic abnormalities or urinary tract infection . PNL can be performed safely and effectively in children by experienced surgeons, resulting in a high stone-free rate and lower requirement for ancillary treatment. In adults, PNL is performed under fluoroscopic or ultrasound guidance. In pediatric age group, fluoroscopic guidance was preferred in most of the reported studies. However, fluoroscopy exposes the patient to radiation. The International Commission on Radiological Protection recommends that whole body exposure in adults should be limited to an effective dose of 20 mSv per year over 5 years. In young children, it is particularly important to protect the developing gonads and thyroid gland, as the long-term effects of exposing these organs to radiation are still unclear. In contrast to fluoroscopic guidance, ultrasound guidance does not expose the patient to radiation, it also can provide real-time monitoring during the puncturing procedure. The path and depth of the needle, and the anatomy in and around the kidney, are clearly visible on ultrasound examination ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03250559
Study type	Interventional
Source	Assiut University
Contact	Ayman Elqady, master
Phone	0020882102113
Email	Dr.uro87@gmail.com
Status	Recruiting
Phase	N/A
Start date	November 20, 2018
Completion date	May 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05169411` - Preserving Kidney Function in Children With Chronic Kidney Disease	N/A
Completed	`NCT05630729` - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management	N/A
Completed	`NCT05569746` - A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS	Phase 2
Completed	`NCT05064267` - Hemostatic Profiles in Pediatric CKD
Not yet recruiting	`NCT06430684` - Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease	Early Phase 1
Recruiting	`NCT04752293` - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Recruiting	`NCT05653492` - Safety, Feasibility, and Tolerability of Sulforaphane in Children With Chronic Kidney Disease	Phase 2
Completed	`NCT05896345` - Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone	N/A
Completed	`NCT06087003` - Pediatric Induction Therapy in Kidney Transplantation
Not yet recruiting	`NCT06286098` - Alpha Lipoic Acid in Pediatrics on Hemodialysis	Phase 3
Completed	`NCT04788394` - Renal Involvement in Hospitalized Children With COVID-19
Recruiting	`NCT05439980` - Improving Phosphate Control in Children With CKD
Completed	`NCT04010981` - Comparison of the Effectiveness of Virtual Reality and Video Assisted Exercises in Pediatric Chronic Kidney Disease.	N/A
Recruiting	`NCT02378805` - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Terminated	`NCT04132375` - Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS	Phase 2/Phase 3
Completed	`NCT04836026` - Registry for HF20 for Pediatric CRRT Under Emergency Use Authorization
Completed	`NCT05388955` - Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Active, not recruiting	`NCT03719339` - VIRTUUS Children's Study
Recruiting	`NCT06057545` - Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.